Drug intelligence / Profile preview

Cranfluxx

Development stage: Unknown
Lead developer: Ruhrpharm
Modality: Small Molecules
Administration: Oral

Overview

Cranfluxx is a nutraceutical supplement developed by Ruhrpharm, primarily indicated for the prevention and management of urinary tract infections (UTIs). The active component is cranberry extract, which is rich in proanthocyanidins (PACs). The primary mechanism of action involves inhibiting the adhesion of uropathogenic bacteria, specifically P-fimbriated *Escherichia coli*, to the uroepithelial cells lining the urinary tract. By preventing bacterial attachment, the supplement facilitates the flushing of bacteria during urination, thereby reducing the risk of colonization and subsequent infection. It is marketed as an approved dietary supplement in Germany.

Brand names: Cranfluxx
Other names: Cranberry extract

Targets

P fimbriae

Beyond the preview

Go deeper on Cranfluxx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cranfluxx.

Explore the full profile